Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04354545 · ClinicalTrials.gov registry record

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

A clinical trial of Glaucoma and Ocular Surface Disease, sponsored by University of California, Los Angeles.

Recruiting
Registry status
75
Enrollment target
1
Study location

NCT04354545 is a study of Glaucoma and Ocular Surface Disease that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 75 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04354545, a study of Glaucoma and Ocular Surface Disease, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
75 participants
Enrollment target
1
Study location

Study Summary

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

Interventions

  • DRUG Xiidra (Lifitegrast ophthalmic solution) 5%

Study Locations (1)

California

  • Doheny Eye Center UCLA - Fountain Valley

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2021-04-01
Est. Completion 2026-12-01

What the Registry Record Tells You About NCT04354545

The ClinicalTrials.gov registry entry for NCT04354545 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (92% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Xiidra (Lifitegrast ophthalmic solution) 5% is the first listed.

NCT04354545 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04354545 about?

NCT04354545 is a clinical study titled "Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications". To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

What is the current status of trial NCT04354545?

This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2021-04-01. Estimated completion is 2026-12-01.

What conditions does trial NCT04354545 study?

This clinical trial studies the following conditions: Glaucoma, Ocular Surface Disease.

What interventions are being tested in trial NCT04354545?

The interventions under investigation include: Xiidra (Lifitegrast ophthalmic solution) 5% (DRUG).

Who is sponsoring clinical trial NCT04354545?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04354545 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.